{"doc_id": "32795330", "type of study": "Therapy", "title": "", "abstract": "Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial.\nCalcium release-activated calcium (CRAC) channel inhibitors stabilize the pulmonary endothelium and block proinflammatory cytokine release, potentially mitigating respiratory complications observed in patients with COVID-19.\nThis study aimed to investigate the safety and efficacy of Auxora, a novel, intravenously administered CRAC channel inhibitor, in adults with severe or critical COVID-19 pneumonia.\nA randomized, controlled, open-label study of Auxora was conducted in adults with severe or critical COVID-19 pneumonia.\nPatients were randomized 2:1 to receive three doses of once-daily Auxora versus standard of care (SOC) alone.\nThe primary objective was to assess the safety and tolerability of Auxora.\nFollowing FDA guidance, study enrollment was halted early to allow for transition to a randomized, blinded, placebo-controlled study.\nIn total, 17 patients with severe and three with critical COVID-19 pneumonia were randomized to Auxora and nine with severe and one with critical COVID-19 pneumonia to SOC.\nSimilar proportions of patients receiving Auxora and SOC experienced \u2265\u20091 adverse event (75% versus 80%, respectively).\nFewer patients receiving Auxora experienced serious adverse events versus SOC (30% versus 50%, respectively).\nTwo patients (10%) receiving Auxora and two (20%) receiving SOC died during the\u00a030\u2009days after randomization.\nAmong patients with severe COVID-19 pneumonia, the median time to recovery with Auxora was 5\u00a0days versus 12\u2009days with SOC; the recovery rate ratio was 1.87 (95% CI, 0.72, 4.89).\nInvasive mechanical ventilation was needed in 18% of patients with severe COVID-19 pneumonia receiving Auxora versus 50% receiving SOC (absolute risk reduction\u2009=\u200932%; 95% CI, -\u20090.07, 0.71).\nOutcomes measured by an 8-point ordinal scale were significantly improved for patients receiving Auxora, especially for patients with a baseline PaO2/FiO2\u2009=\u2009101-200.\nAuxora demonstrated a favorable safety profile in patients with severe or critical COVID-19 pneumonia and improved outcomes in patients with severe COVID-19 pneumonia.\nThese results, however, are limited by the open-label study design and small patient population resulting from the early cessation of enrollment in response to regulatory guidance.\nThe impact of Auxora on respiratory complications in patients with severe COVID-19 pneumonia will be further assessed in a planned randomized, blinded, placebo-controlled study.\nTRIAL REGISTRATION : ClinicalTrials.gov, NCT04345614 .\nSubmitted on 7 April 2020.\n", "Evidence Map": {"Enrollment": [{"term": "severe or critical COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 89}, {"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 139}, {"term": "severe or", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 154}, {"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 78}, {"term": "severe or critical", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 102}, {"term": "severe", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 34}, {"term": "critical COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 77}, {"term": "severe", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 34}, {"term": "critical COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 77}, {"term": "severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 45}, {"term": "severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 93}, {"term": "severe or critical COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 101}, {"term": "severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 141, "end": 166}, {"term": "severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 92}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia : results from a randomized controlled trial .", "Evidence Elements": {"Participant": [{"term": "severe or critical COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 89}], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6, "has_relation": "N/A"}, {"term": "standard of care", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 30, "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Calcium release-activated calcium ( CRAC ) channel inhibitors stabilize the pulmonary endothelium and block proinflammatory cytokine release , potentially mitigating respiratory complications observed in patients with COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "complications", "negation": "affirmed", "UMLS": {}, "start": 178, "end": 191}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "This study aimed to investigate the safety and efficacy of Auxora , a novel , intravenously administered CRAC channel inhibitor , in adults with severe or critical COVID-19 pneumonia .", "Evidence Elements": {"Participant": [{"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 139}, {"term": "severe or", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 154}], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 65, "has_relation": "N/A"}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 42}, {"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 55}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "A randomized , controlled , open-label study of Auxora was conducted in adults with severe or critical COVID-19 pneumonia .", "Evidence Elements": {"Participant": [{"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 78}, {"term": "severe or critical", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 102}], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 54, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomized 2:1 to receive three doses of once-daily Auxora versus standard of care ( SOC ) alone .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "three doses of once-daily Auxora", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 72, "has_relation": "N/A"}, {"term": "standard of care ( SOC", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 102, "has_procedure": [{"text": "standard of care standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 33}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary objective was to assess the safety and tolerability of Auxora .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 73, "has_relation": "N/A"}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 46}, {"term": "tolerability", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 63}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Following FDA guidance , study enrollment was halted early to allow for transition to a randomized , blinded , placebo-controlled study .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "In total , 17 patients with severe and three with critical COVID-19 pneumonia were randomized to Auxora and nine with severe and one with critical COVID-19 pneumonia to SOC .", "Evidence Elements": {"Participant": [{"term": "severe", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 34}, {"term": "critical COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 77}, {"term": "severe", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 34}, {"term": "critical COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 77}], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 103, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Similar proportions of patients receiving Auxora and SOC experienced \u2265 1 adverse event ( 75 % versus 80 % , respectively ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 48, "has_relation": "N/A"}, {"term": "SOC", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 56, "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}], "Outcome": [{"term": "\u2265 1 adverse event", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 86}], "Observation": [{"term": "Similar proportions", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 19}, {"term": "patients", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 31}, {"term": "75 %", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 93}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "Auxora", "has_relation": "N/A"}, {"term": "SOC", "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}], "Observation": "Similar proportions", "Outcome": "\u2265 1 adverse event", "Count": ""}, {"Intervention": {"term": "Auxora", "has_relation": "N/A"}, "Observation": "patients", "Outcome": "\u2265 1 adverse event", "Count": ""}, {"Intervention": {"term": "Auxora", "has_relation": "N/A"}, "Observation": "75 %", "Outcome": "\u2265 1 adverse event", "Count": ""}, {"Intervention": {"term": "SOC", "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}, "Observation": "75 %", "Outcome": "\u2265 1 adverse event", "Count": ""}]}, {"Section": "RESULTS", "Text": "Fewer patients receiving Auxora experienced serious adverse events versus SOC ( 30 % versus 50 % , respectively ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 31, "has_relation": "N/A"}, {"term": "SOC", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 77, "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}], "Outcome": [{"term": "serious adverse events", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 66}], "Observation": [{"term": "Fewer patients", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}, {"term": "30 %", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 84}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "Auxora", "has_relation": "N/A"}, {"term": "SOC", "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}], "Observation": "Fewer patients", "Outcome": "serious adverse events", "Count": ""}, {"Intervention": {"term": "Auxora", "has_relation": "N/A"}, "Observation": "30 %", "Outcome": "serious adverse events", "Count": ""}, {"Intervention": {"term": "SOC", "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}, "Observation": "30 %", "Outcome": "serious adverse events", "Count": ""}]}, {"Section": "RESULTS", "Text": "Two patients ( 10 % ) receiving Auxora and two ( 20 % ) receiving SOC died during the 30 days after randomization .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 38, "has_relation": "N/A"}, {"term": "SOC", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 69, "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}], "Outcome": [{"term": "died", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 74}], "Observation": [], "Count": [{"term": "Two patients ( 10 % )", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 21}, {"term": "two ( 20 % )", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 55}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Among patients with severe COVID-19 pneumonia , the median time to recovery with Auxora was 5 days versus 12 days with SOC ; the recovery rate ratio was 1.87 ( 95 % CI , 0.72 , 4.89 ) .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 45}], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 87, "has_relation": "N/A"}, {"term": "SOC", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 122, "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}], "Outcome": [{"term": "median time to recovery", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 75}, {"term": "recovery rate ratio", "negation": "affirmed", "UMLS": {}, "start": 129, "end": 148}], "Observation": [{"term": "5 days", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 98}, {"term": "12 days", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 113}, {"term": "1.87", "negation": "affirmed", "UMLS": {}, "start": 153, "end": 157}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "Auxora", "has_relation": "N/A"}, "Observation": "5 days", "Outcome": "median time to recovery", "Count": ""}, {"Intervention": {"term": "SOC", "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}, "Observation": "12 days", "Outcome": "median time to recovery", "Count": ""}]}, {"Section": "RESULTS", "Text": "Invasive mechanical ventilation was needed in 18 % of patients with severe COVID-19 pneumonia receiving Auxora versus 50 % receiving SOC ( absolute risk reduction = 32 % ; 95 % CI , -0.07 , 0.71 ) .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 93}], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 104, "end": 110, "has_relation": "N/A"}, {"term": "SOC", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 136, "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}], "Outcome": [{"term": "Invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 31}], "Observation": [{"term": "needed", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 42}], "Count": [{"term": "18 % of patients", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 62}, {"term": "50 %", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 122}]}, "Evidence Propositions": [{"Intervention": {"term": "Auxora", "has_relation": "N/A"}, "Observation": "needed", "Outcome": "Invasive mechanical ventilation", "Count": ""}, {"Intervention": {"term": "Auxora", "has_relation": "N/A"}, "Observation": "", "Count": "18 % of patients", "Outcome": "Invasive mechanical ventilation"}]}, {"Section": "RESULTS", "Text": "Outcomes measured by an 8-point ordinal scale were significantly improved for patients receiving Auxora , especially for patients with a baseline PaO2 / FiO2 = 101-200 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 103, "has_relation": "N/A"}], "Outcome": [], "Observation": [{"term": "significantly improved", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 73}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "Auxora demonstrated a favorable safety profile in patients with severe or critical COVID-19 pneumonia and improved outcomes in patients with severe COVID-19 pneumonia .", "Evidence Elements": {"Participant": [{"term": "severe or critical COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 101}, {"term": "severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 141, "end": 166}], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6, "has_relation": "N/A"}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 38}, {"term": "outcomes", "negation": "affirmed", "UMLS": {}, "start": 115, "end": 123}], "Observation": [{"term": "favorable", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 31}, {"term": "improved", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 114}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "These results , however , are limited by the open-label study design and small patient population resulting from the early cessation of enrollment in response to regulatory guidance .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "The impact of Auxora on respiratory complications in patients with severe COVID-19 pneumonia will be further assessed in a planned randomized , blinded , placebo-controlled study .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 92}], "Intervention": [{"term": "Auxora", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 20, "has_relation": "N/A"}], "Outcome": [{"term": "respiratory complications", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 49}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION : ClinicalTrials.gov , NCT04345614 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Submitted on 7 April 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}